VSee Health a leading provider of HIPAA-compliant digital health solutions has been selected to support a NIH-funded Phase 3 clinical trial study on stroke recovery telerehabilitation based out of UCLA—the second such national trial of post-stroke telerehabilitation. The trial spans 29 hospitals and 202 patients, and will evaluate the outcomes of adding 6 weeks of gamified, home-based telerehab to improve arm functionality in stroke survivors while reducing costs like transportation, caregiver burdens, and hospital readmissions.
Health Technology Insights: Sling Therapeutics Appoints Ken Lock as Chief Commercial Officer
This Phase 3 trial…positions VSee as the go-to platform for the next wave of value-based virtual care that improves outcomes while reducing costs.
The proven efficacy of Phase 3 trials opens doors for Medicare and private payer reimbursement and opportunities in the $328M global stroke rehab market, where telehealth could disrupt traditional physical therapy with better adherence and lower costs. Success also paves the way for gamified telerehabilitation in other areas, e.g. multiple sclerosis, spinal cord injury, and traumatic brain injury rehab.
Health Technology Insights: NaphCare Launches TechCare BI to Enhance Correctional EHR
Professor of neurology at UCLA and a co-principal investigator, Dr. Steven Cramer, MD affirms, “Reaching Phase 3 in a clinical trial of this scale is a hard-won milestone that has been twelve years in the making—one that wouldn’t have been possible without the right partners. VSee Health’s HIPAA-compliant platform has been instrumental in ensuring secure, seamless delivery of our interventions—critical for maintaining compliance and engagement in a large-scale trial like this.”
Dr. Milton Chen, PhD, Co-CEO of VSee Health adds, “We’re grateful and proud of VSee’s role in two of the only nationwide U.S. stroke tele-rehab trials. This Phase 3 trial validates telehealth as a scalable, cost-effective model for neurorehabilitation, and positions VSee as the go-to platform for the next wave of value-based virtual care that improves outcomes while reducing costs.”
This trial further solidifies VSee’s position as a key player in the telerehab market, building on VSee’s prior role in Phase 1 and Phase 2 of this neurology study.
Enrollment for the clinical trial begins Q3 2025, with the study combining independent and remote therapist-supervised games and exercises via VSee to overcome barriers like limited access to physical therapy clinics and poor patient motivation.
Health Technology Insights: Quest Health, Rimidi Partner to Improve Diabetes RPM Outcomes
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
